Core Points - The company announced an adjustment to the conversion price of its convertible bonds "Hao Yuan Convertible Bonds" due to the completion of share repurchase and cancellation related to performance commitments [1][3] - The previous conversion price was 40.58 CNY/share, and the new conversion price is adjusted to 40.59 CNY/share, effective from July 8, 2025 [2][5] - The company issued 822,350 lots (8,223,500 bonds) of convertible bonds totaling 82,235 million CNY, with a maturity of 6 years and an initial conversion price of 40.73 CNY/share [2][3] Adjustment Basis - The adjustment of the conversion price is based on the completion of the repurchase and cancellation of 47,725 shares at a total price of 1.00 CNY, as approved in board meetings and the annual shareholders' meeting [3][4] - The company followed the regulations set by the China Securities Regulatory Commission regarding the issuance of convertible bonds and the related adjustments to protect the rights of bondholders [3][5] Adjustment Methodology - The adjustment formula used for the conversion price is P1 = (P0 + A × k) / (1 + k), where P0 is the previous conversion price, A is the new share price, and k is the rate of share repurchase [5] - The calculation resulted in the new conversion price of approximately 40.59 CNY/share after the repurchase and cancellation of shares [5][6]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-085 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整可转换公司债券"皓元转债"转股价格暨 转股停复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因业绩承诺补偿股份回购注销实施完成导致"皓元转债"转股价格调整,本公 司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | | | | 118051 | 皓元转债 | 可转债转股 | 2025/7/7 | 全天 | 2025/7/7 | 2025/7/8 | | | | 停牌 | | | | | "皓元转债"调整前转股价格：40.58 元/股 经中国证券监督管理委员会《关于同意 ...

证券代码：688131 证券简称：皓元医药 公告编号：2025-084 转债代码：118051 转债简称：皓元转债 上海皓元医药股份有限公司 关于业绩承诺补偿股份回购注销实施结果暨 股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 因药源药物化学（上海）有限公司（以下简称"药源药物"）未能实现业 绩承诺，业绩承诺方 WANG YUAN、上海源盟企业管理咨询合伙企业（有限合伙） （以下简称"上海源盟"）、上海源黎企业管理合伙企业（有限合伙） （以下简称"上 海源黎"）需对上海皓元医药股份有限公司（以下简称"公司"）进行业绩补偿。 公司以人民币 1 元的总价格回购业绩承诺方合计持有的公司股份 47,725 股，占回 购注销前公司总股本 211,609,573 股的 0.02%，并全部予以注销。 ? 公司于 2025 年 7 月 3 日收到中国证券登记结算有限责任公司上海分公司 出具的《证券过户登记确认书》，业绩承诺方持有公司的 47,725 股股票已过户至公 司回购专用证券账户。 ? 本次回购的 ...

因药源药物化学（上海）有限公司（以下简称"药源药物"）未能实现业 绩承诺，业绩承诺方 WANG YUAN、上海源盟企业管理咨询合伙企业（有限合伙） （以下简称"上海源盟"）、上海源黎企业管理合伙企业（有限合伙）（以下简称"上 海源黎"）需对上海皓元医药股份有限公司（以下简称"公司"）进行业绩补偿。 公司以人民币 1 元的总价格回购业绩承诺方合计持有的公司股份 47,725 股，占回 购注销前公司总股本 211,609,573 股的 0.02%，并全部予以注销。 公司于 2025 年 7 月 3 日收到中国证券登记结算有限责任公司上海分公司 出具的《证券过户登记确认书》，业绩承诺方持有公司的 47,725 股股票已过户至公 司回购专用证券账户。 | 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-084 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于业绩承诺补偿股份回购注销实施结果暨 股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、 ...

皓元医药公告，因药源药物化学(上海)有限公司未能实现业绩承诺，业绩承诺方WANG YUAN、上海源 盟、上海源黎需对公司进行业绩补偿。公司以人民币1元的总价格回购业绩承诺方合计持有的公司股份 47725股，占回购注销前公司总股本2.12亿股的0.02%，并全部予以注销。公司于2025年7月3日收到中国 证券登记结算有限责任公司上海分公司出具的《证券过户登记确认书》，业绩承诺方持有公司的47725 股股票已过户至公司回购专用证券账户。本次回购的47725股股票将于2025年7月4日全部注销，公司总 股本将由2.12亿股变更为2.12亿股，注册资本由2.12亿元人民币变更为2.12亿元人民币。 ...

Core Viewpoint - The company, Haoyuan Pharmaceutical, is enhancing the competitiveness of its wholly-owned subsidiary, Anhui Haoyuan, by implementing a capital increase through debt-to-equity conversion, amounting to 400 million yuan, to alleviate financial pressure and optimize its capital structure [1][4]. Group 1: Financial Performance - In Q1 2025, Haoyuan Pharmaceutical reported revenue of 606 million yuan, a year-on-year increase of 20.05%, and a net profit of 62.38 million yuan, up 272.28% [1][5]. - For the year 2024, the company achieved revenue of 2.27 billion yuan, a growth of 20.75%, and a net profit of 202 million yuan, reflecting a 58.17% increase [5][6]. - The R&D expenses for Q1 2025 were 53.71 million yuan, accounting for 8.86% of the revenue [1]. Group 2: Debt-to-Equity Conversion Details - The capital increase will raise Anhui Haoyuan's registered capital from 400 million yuan to 800 million yuan, maintaining its status as a wholly-owned subsidiary of Haoyuan Pharmaceutical [1][4]. - This is the second instance of debt-to-equity conversion for Anhui Haoyuan, following a previous increase of 200 million yuan in March 2024 [3][4]. Group 3: Business Operations and Market Position - Haoyuan Pharmaceutical focuses on providing efficient small molecule and new molecular type drugs for the global pharmaceutical and biopharmaceutical industries, continuously enhancing its market competitiveness through product pipeline expansion and technological iteration [1][5]. - The life science reagent business generated approximately 1.5 billion yuan in revenue in 2024, accounting for about 66% of total revenue, with a gross margin of 62.21% [6]. - The company has a total of 403 generic drug projects and 892 innovative drug projects, with many in the clinical trial stages, contributing to the global innovative drug development process [6].

Core Viewpoint - The company announced that the conversion price of its convertible bonds, "Haoyuan Convertible Bonds," will remain unchanged at RMB 40.58 per share following the completion of its stock incentive plan [1][4][6] Group 1: Convertible Bond Issuance - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and an initial conversion price set at RMB 40.73 per share [1] - The bonds will be listed on the Shanghai Stock Exchange on December 19, 2024, with a total issuance of 822,350 lots (8,223,500 bonds) [1] Group 2: Stock Incentive Plan and Price Adjustment - The company completed the registration of the third vesting period of its 2022 restricted stock incentive plan on June 30, 2025, increasing its total share capital from 210,961,003 shares to 211,609,573 shares [2] - The adjustment of the conversion price is based on the company's stock incentive plan and follows specific formulas outlined in the bond issuance prospectus [3][5] Group 3: Price Adjustment Calculation - The conversion price remains unchanged at RMB 40.58 per share because the total number of shares from the stock incentive plan is relatively small compared to the total share capital [4][6] - The calculation for the conversion price adjustment was performed using the formula for new share issuance, resulting in no change to the conversion price [5][6]

Core Points - Shanghai Haoyuan Pharmaceutical Co., Ltd. issued 8.2235 million convertible bonds with a total amount of 82.235 million RMB, with a maturity of 6 years [1] - The convertible bonds, named "Haoyuan Convertible Bonds," will be listed on the Shanghai Stock Exchange starting December 19, 2024 [1] - The initial conversion price is set at 40.73 RMB per share, effective from June 4, 2025, until November 27, 2030 [2] Convertible Bond Issuance Overview - The company completed the registration procedures for the first vesting period of the 2022 restricted stock incentive plan, increasing the total share capital from 210,928,884 shares to 210,959,781 shares [2] - The conversion price of the "Haoyuan Convertible Bonds" remains unchanged at 40.73 RMB per share after the completion of the vesting [2] - The conversion price will be adjusted to 40.58 RMB per share starting May 14, 2025, due to the annual equity distribution [3] Conversion Status - From June 4, 2025, to June 30, 2025, a total of 1,222 shares were converted from the "Haoyuan Convertible Bonds," representing 0.0006% of the total shares before conversion [4] - As of June 30, 2025, the amount of unconverted bonds stands at 822.3 million RMB, accounting for 99.99% of the total issuance [5] Share Capital Changes - Following the completion of the vesting procedures, the total share capital increased to 211,609,573 shares, with 648,570 shares from the incentive plan becoming tradable on July 8, 2025 [5] Additional Information - Investors can refer to the detailed prospectus for the "Haoyuan Convertible Bonds" issued on November 26, 2024, for more information [6]

Core Viewpoint - The announcement details the results of the third vesting period of the 2022 Restricted Stock Incentive Plan and the second vesting period of the reserved portion, with a total of 648,570 shares set to be listed for trading on July 8, 2025 [1][15]. Summary by Sections Important Content Highlights - The total number of shares for this stock listing is 648,570, which is part of the equity incentive shares [1]. - The vesting registration for the third vesting period and the reserved portion's second vesting period was completed on June 30, 2025 [1]. Decision-Making Process and Disclosure - The board of directors approved the incentive plan on January 26, 2022, with independent directors and legal advisors providing their consent [2][5]. - The proposed list of incentive recipients was publicly disclosed from January 27 to February 5, 2022, with no objections received [3]. - The shareholders approved the incentive plan at a meeting on February 15, 2022 [4]. Vesting Details - For the first grant portion, 84 individuals received a total of 480,868 shares, representing 39.92% of the total granted shares [10]. - The reserved portion had 20 individuals eligible for 167,702 shares, with 50% of the reserved shares vesting [11][13]. Stock Listing and Capital Changes - The total share capital increased from 210,961,003 to 211,609,573 shares due to this vesting [14]. - The company received a total of RMB 25,553,658.00 from the incentive recipients, contributing to an increase in share capital and capital reserves [15]. Financial Impact - The basic earnings per share for Q1 2025 will be diluted due to the increase in total shares, with the net profit for the period reported at RMB 62,384,400.02 [15].

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-082 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司关于不调整可转换公司 债券"皓元转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海皓 元医药股份有限公司（以下简称"公司"）向不特定对象发行 82,235.00 万元的 可转换公司债券，期限 6 年，每张面值为人民币 100 元，发行数量为 822,350 手 （8,223,500 张），于 2024 年 12 月 19 日在上海证券交易所挂牌交易，债券简称 "皓元转债"，债券代码"118051"，初始转股价格为人民币 40.73 元/股，经历 次调整，截至本次转股价格调整前，"皓元转债"的转股价格为 40.58 元/股。转 股期间为 ...